Arca
Skip to content
Tools
Tools

FOLH1: Glutamate carboxypeptidase 2

Has both folate hydrolase and N-acetylated-alpha-linked- acidic dipeptidase (NAALADase) activity.

  • Drugs that act on it: 8
  • Approved: 1
  • In phases 1 to 3: 7
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on FOLH1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1
  • Protein or peptide 1
  • Other 6

Approved1

Phase 30

    Phase 25

    • J591 177LU
    • HUJ591 111IN
    • HUJ591 177LU
    • MDX-070
    • Yttrium y 90 capromab pendetide

    Phase 12

    • CYT-500 177LU
    • MLN-2704

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 7 of 8 act as: Glutamate carboxypeptidase II binding agent; the rest name their own mechanism.
    Vipivotide tetraxetan lutetiumApprovedNovartis PharmaceuticalsProtein or peptideBinding agent38
    J591 177LUPhase 2—OtherBinding agent3
    HUJ591 111INPhase 2—OtherBinding agent1
    HUJ591 177LUPhase 2—OtherBinding agent1
    MDX-070Phase 2—OtherOtherGlutamate carboxypeptidase II other0
    Yttrium y 90 capromab pendetidePhase 2—AntibodyBinding agent0
    CYT-500 177LUPhase 1CytogenOtherBinding agent0
    MLN-2704Phase 1Takeda Pharmaceuticals USAOtherBinding agent0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 11 in all, from ClinicalTrials.gov.
    A Study of Real-world Effectiveness of 177Lu-PSMA-617 With and Without Concurrent Androgen Receptor Pathway Inhibitors in Metastatic Castration Resistant Prostate Cancer PatientsVipivotide tetraxetan lutetium—Not yet recruitingNovartis PharmaceuticalsNov 10, 2026
    Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate CancerVipivotide tetraxetan lutetiumPhase 2Not yet recruitingEmory UniversityOct 6, 2026
    Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate CancerVipivotide tetraxetan lutetiumPhase 2 / Phase 3Not yet recruitingECOG-ACRIN Cancer Research GroupOct 1, 2026
    LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide TetraxetanVipivotide tetraxetan lutetiumPhase 2Not yet recruitingThomas Jefferson UniversityJul 30, 2026
    Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO TrialVipivotide tetraxetan lutetiumPhase 2RecruitingUniversity of WashingtonJul 13, 2026
    Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate CancerVipivotide tetraxetan lutetiumPhase 1Not yet recruitingUniversity of Michigan Rogel Cancer CenterJul 6, 2026
    Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE TrialVipivotide tetraxetan lutetiumPhase 2RecruitingMayo ClinicJun 16, 2026
    PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide TetraxetanVipivotide tetraxetan lutetium—RecruitingNovartis PharmaceuticalsMar 20, 2026
    Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate CancerJ591 177LUPhase 1RecruitingWeill Medical College of Cornell UniversityMay 14, 2021
    Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPCJ591 177LUPhase 1Active, not recruitingWeill Medical College of Cornell UniversityAug 10, 2020
    177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate CancerHUJ591 111IN, HUJ591 177LU, J591 177LUPhase 2Active, not recruitingWeill Medical College of Cornell UniversityMar 11, 2009

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Type 2 diabetes mellitus0.36
    • Retinal disorder0.34
    • Clear cell renal carcinoma0.30
    • Neuroendocrine neoplasm0.29
    • Arthropathy0.28
    • Epiretinal membrane0.27
    • Cor pulmonale0.27

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1892, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt Q04609, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.